PSEN1 and Alzheimer disease: One of the major research aims in this work has been to examine the possibility that, despite the unchanged protein levels in the APP/PS1 model of AD, GABAB receptors may still undergo changes in their localization along the plasma membrane vs. cytoplasmic sites with pathology progression.